David S. Siegel

Oncology | Hematology

92 2nd Street
Hackensack, NJ 7601.

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 181 publications

Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma.

Characterization and prognostic implications of infections associated with T-cell engagers in multiple myeloma.

Journal: Leukemia & lymphoma

Published: August 11, 2026

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Overcoming Trial Exclusion: A Multicenter Analysis of Hemodialysis Multiple Myeloma Patients Who Underwent BCMA-Directed CAR-T Therapy.

Journal: Current oncology (Toronto, Ont.)

Published: June 27, 2026

Using cell-free RNA to identify B- and T-cell clonality for diagnosis and monitoring of B- and T-cell neoplasms.

Using cell-free RNA to identify B- and T-cell clonality for diagnosis and monitoring of B- and T-cell neoplasms.

Journal: FEBS open bio

Published: June 07, 2026

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Combined Immune Checkpoint Inhibitors and Radiation Therapy in Patients with Multiple Myeloma and Extramedullary Medullary Disease: A Real-World Retrospective Analysis.

Journal: Cancers

Published: May 18, 2026

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.

Consolidation Therapy with Checkpoint Inhibitors After Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Multiple Myeloma and Lymphoma.

Journal: Transplantation and cellular therapy

Published: March 11, 2026

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Salvage Therapy in Multiple Myeloma With Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination With Pomalidomide.

Journal: European journal of haematology

Published: January 09, 2026

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.

Journal: Leukemia & lymphoma

Published: December 02, 2025

Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.

Vestibular Symptoms Following Talquetamab Therapy in Heavily Pretreated Multiple Myeloma.

Journal: Blood advances

Published: November 03, 2025

Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

Vestibular symptoms after talquetamab therapy in heavily pretreated multiple myeloma.

Journal: Blood advances

Published: November 03, 2025

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Linvoseltamab versus real-world International Myeloma Working Group standard-of-care in triple-class exposed relapsed/refractory multiple myeloma.

Journal: Blood cancer journal

Published: August 07, 2025

Combining antigen specific T-cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness.

Combining antigen specific T-cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness.

Journal: Blood immunology & cellular therapy

Published: July 07, 2025

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Author Correction: Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes.

Journal: Nature genetics

Published: June 09, 2025

Showing 1-12 of 181

Last Updated: 09/26/2026